New Drugs Update: Three Novel Treatments for SARS-CoV-2.

Sr Care Pharm

Harding University, Searcy, Arkansas.

Published: August 2022

Coronavirus disease 2019 (COVID-19) cases were first reported in China in December 2019. As of June 4, 2022, more than 530 million cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have been reported globally, including more than 6.2 million deaths. People of all ages are at risk for SARS-CoV-2 infection and severe illness; however, the probability of serious COVID-19 disease is higher in people 60 years of age or older, those living in a nursing facility or long-term care facility, and people with chronic medical conditions. Mortality is highest in patients older than 70 years of age, regardless of the presence of chronic medical conditions.² In the last two years, in addition to emergence of COVID-19 testing and vaccines, several antiviral treatments and monoclonal antibodies (mAbs) became available and can be used to reduce their chances of being hospitalized or dying from the disease.

Download full-text PDF

Source
http://dx.doi.org/10.4140/TCP.n.2022.317DOI Listing

Publication Analysis

Top Keywords

years age
8
chronic medical
8
drugs update
4
update three
4
three novel
4
novel treatments
4
treatments sars-cov-2
4
sars-cov-2 coronavirus
4
coronavirus disease
4
disease 2019
4

Similar Publications

This study examined the effect of lymphedema self-care patient school education on patient functionality, quality of life, body value, and lymphedema volume in patients with lower extremity lymphedema. The study utilized a single-group quasi-experimental design. The study sample included 21 patients with primary and secondary lower extremity lymphedema.

View Article and Find Full Text PDF

Objective: We investigated associations between per- and polyfluoroalkyl substances (PFAS) and changes in diabetes indicators from pregnancy to 12 years after delivery among women with a history of gestational diabetes mellitus (GDM).

Research Design And Methods: Eighty Hispanic women with GDM history were followed from the third trimester of pregnancy to 12 years after delivery. Oral and intravenous glucose tolerance tests were conducted during follow-up.

View Article and Find Full Text PDF

Severe Maternal Morbidity Associated With Chronic Hypertension, Preeclampsia, and Gestational Hypertension.

JAMA Netw Open

January 2025

Magee-Womens Research Institute, Department of Obstetrics, Gynecology and Reproductive Sciences, Epidemiology and Clinical and Translational Research, University of Pittsburgh, Pittsburgh, Pennsylvania.

Importance: Chronic hypertension and preeclampsia are leading risk enhancers for maternal-neonatal morbidity and mortality. Severe maternal morbidity (SMM) indicators include heart, kidney, and liver disease, but studies have not excluded patients with preexisting diseases that define SMM. Thus, SMM risks for uncomplicated chronic hypertension specific to preeclampsia remain unclear.

View Article and Find Full Text PDF

Phenotypic Classification of Multisystem Inflammatory Syndrome in Children Using Latent Class Analysis.

JAMA Netw Open

January 2025

Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Importance: Multisystem inflammatory syndrome in children (MIS-C) is an uncommon but severe hyperinflammatory illness that occurs 2 to 6 weeks after SARS-CoV-2 infection. Presentation overlaps with other conditions, and risk factors for severity differ by patient. Characterizing patterns of MIS-C presentation can guide efforts to reduce misclassification, categorize phenotypes, and identify patients at risk for severe outcomes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!